Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. Investigators aim to obtain reference data for individuals with T1D who do not have overweight obesity, to understand how close GLP-1 analogue obesity treatment in those with overweight/obesity brings physiologic markers of cardiometabolic risk to those with BMI in the normal range. Specifically, investigators will describe how drivers of gluconeogenesis and lipemia (specifically measured as visceral fat ratio, insulin resistance, and postprandial lipemia,) that contribute to cardiometabolic risk in T1D change over time.
• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, aged 18 to ≤30 years
• Diagnosed T1D for at least 12 months and with BMI \<25 kg/m2.
• HbA1c ≤10%
• Clinical use of continuous glucose monitoring (CGM)
• Any known laboratory safety parameter consistently outside the below extended laboratory ranges in the past year:
‣ Baseline creatinine \>1.0mg
⁃ Hypertriglyceridemia (\>400 mg/dl)
⁃ ALT ≥3.5 times the upper normal limit (UNL)